Vaccine equity means that everyone has a fair opportunity to be vaccinated, regardless of their income, race, ethnicity, or where they live. It sounds simple, but the gap between that goal and reality is enormous. In 2023, 94% of children in high-income countries received basic childhood vaccines, compared to just 70% in low-income countries. That 24-point gap represents millions of children left unprotected against preventable diseases.
Equity vs. Equality in Vaccination
Equality means giving everyone the same resources. Equity means giving people what they actually need to reach the same outcome. In vaccination, this distinction matters. Shipping identical quantities of vaccines to every country regardless of infrastructure, refrigeration capacity, or staffing levels treats everyone “equally” but doesn’t produce equal results. A rural clinic in a low-income country with one nurse and no reliable electricity needs fundamentally different support than a well-funded urban hospital.
Vaccine equity requires identifying the specific barriers different communities face and addressing them directly. That could mean mobile vaccination teams for remote populations, community health workers who speak local languages, or financing mechanisms that make newer vaccines affordable for countries that can’t negotiate bulk pricing.
Why the Gap Exists
Several forces drive vaccine inequity, and they reinforce each other. The most significant include:
- Manufacturing concentration. The vast majority of vaccine production happens in a handful of countries. When demand surges, as it did during COVID-19, wealthier nations secure supply first through advance purchase agreements, leaving lower-income countries waiting months or years longer.
- Intellectual property protections. Patent laws prevent most countries from producing their own versions of newer vaccines. During the pandemic, India and South Africa proposed waiving these protections to let generic manufacturers scale up production. After nearly two years of debate, the World Trade Organization agreed in June 2022 to a limited, five-year waiver covering only COVID-19 vaccines. South Africa pointed out that existing voluntary licensing deals often imposed geographic restrictions that blocked exports to other developing countries.
- Declining funding. International financing for immunization programs has trended downward in recent years, even after the pandemic exposed how dangerous these gaps can be. Countries with fragile health systems or ongoing conflict are hit hardest.
- Weak health infrastructure. Vaccines need cold chains, trained staff, reliable data systems, and community trust. Many low-income countries lack one or more of these, which means even donated vaccines can go unused.
What Happened During COVID-19
The pandemic turned vaccine equity from an abstract policy goal into a visible global crisis. Wealthy nations secured billions of doses through direct deals with manufacturers before vaccines were even approved. By the time lower-income countries gained meaningful access, many had already endured devastating waves of illness and death without the protection that was available elsewhere.
The economic damage was lopsided, too. The International Monetary Fund estimated that global GDP dropped 3.1% in 2020. While advanced economies took the initial hit, lower-income countries bore the heavier long-term burden through 2021 and beyond. A more equitable distribution of vaccines would have accelerated recovery in poorer nations, which in turn would have benefited wealthier countries by restoring global supply chains and reducing the risk of new variants circulating internationally.
Researchers have suggested that leaving large populations unvaccinated increases the chance of new, immune-evasive variants emerging. The logic is straightforward: more viral spread means more opportunities for mutation. While definitive proof of this specific chain of events remains limited, the broader principle that uncontrolled outbreaks anywhere pose risks everywhere became a central argument for equity during the pandemic.
Global Efforts to Close the Gap
COVAX, the international initiative coordinated through Gavi (the Vaccine Alliance), delivered 2 billion doses of COVID-19 vaccines to 146 countries. It was the largest vaccine equity effort ever attempted, though critics noted it was too slow and too dependent on donations from wealthy nations that prioritized their own populations first.
Gavi’s current strategy focuses on long-term sustainability rather than emergency response. Its goals include helping countries build immunization programs that don’t depend permanently on donor funding, creating healthier vaccine markets with more manufacturers and competitive pricing, and reaching “zero-dose children,” those who have never received any vaccine at all. A core principle of the strategy is that countries should eventually transition out of donor support entirely, with agencies working toward defined endpoints rather than open-ended aid relationships.
The WHO’s Immunization Agenda 2030 sets specific global targets: 90% coverage for essential childhood and adolescent vaccines, cutting the number of completely unvaccinated children in half, and completing 500 national or subnational introductions of newer vaccines like those for rotavirus and HPV. These are ambitious benchmarks. Low-income countries saw their basic childhood vaccine coverage drop 7 percentage points between 2019 and 2023, from 75% to 68%, while other income groups largely recovered to pre-pandemic levels.
Vaccine Equity Within Countries
The equity gap isn’t only between nations. Within any single country, vaccination rates often vary sharply by neighborhood, income level, and race. During the U.S. COVID-19 rollout, public health agencies used tools like the CDC’s Social Vulnerability Index to identify communities most likely to face barriers to vaccination. Counties with high social vulnerability were more likely to become COVID-19 hotspots, and the National Academies of Science recommended using these vulnerability measures to guide where vaccines, testing supplies, and outreach workers were deployed.
Barriers within wealthy countries look different from those in low-income nations but are no less real: lack of transportation, inflexible work schedules that make clinic visits difficult, language barriers, and distrust rooted in historical mistreatment by medical systems.
What Works: Rwanda’s Approach
Rwanda offers one of the clearest examples of a lower-income country achieving strong vaccine coverage through deliberate system design. The country launched an electronic immunization registry called e-Tracker in 2019, built on a widely used open-source health data platform. The system tracks which children have been vaccinated, flags those who have missed doses, and gives health workers real-time data to follow up.
The technology sits on top of an existing network of community health workers at the village level who engage directly with families to raise awareness about childhood immunization. Rwanda is one of the few countries in Africa to implement an electronic immunization registry at national scale, and it backed the system with trained staff at every health center. The model shows that strong coverage doesn’t require massive budgets. It requires political commitment, a functioning community health workforce, and data systems that catch children before they fall through the cracks.
Why It Matters Beyond Health
Vaccine inequity costs more than lives, though that alone should be sufficient reason to address it. Children who miss vaccines are more likely to face repeated illness, which pulls them out of school. The pandemic caused enormous learning losses in countries where prolonged outbreaks and lockdowns continued long after wealthier nations had reopened. Economic recovery stalls when a workforce is repeatedly sidelined by preventable disease. And in an interconnected world, outbreaks that take hold in one region can disrupt supply chains, travel, and trade globally.
The 24-point gap in basic childhood vaccination between rich and poor countries is not a natural phenomenon. It reflects decisions about how vaccines are manufactured, priced, distributed, and prioritized. Closing that gap requires changes at every level, from international trade rules to the last mile of vaccine delivery in a rural clinic.